Once relegated to the domains of science fiction, modern day scientists and researchers are poised on the precipice of making genome editing clinically available. Once introduced into a clinical setting the effects of an off-target mutation or germline edit will remain largely unknown until health issues arise later in life or in the following generation. The novelty of the injuries that will arise require a system that is able to balance the interests of physicians with single and multi-generational plaintiffs, while providing a realistic framework for courts to follow. This comment offers a brand-new context that accounts for these needs and sets expectations for how to handle these injuries in the right way, promulgating the goals of tort law.
CRISPR/Cas-9 Technologies: A Call for a New Form of Tort,
San Diego Int'l L.J.
Available at: https://digital.sandiego.edu/ilj/vol19/iss2/7